The Supreme Court Decision(s) in Myriad: What Did the Justices Say? What Does it Mean for Industry?

26 June 2013 Web Conference Past Event

Location

Web Conference

Contact Information

Meg Ryan
mryan@foley.com

Our panelists will analyze the decision and discuss what it means for the biotechnology industry and the evolving area of patent-eligibility jurisprudence as a whole.

Featured Guest Speakers:

  • The Honorable Paul R. Michel (ret.), United States Court of Appeals for the Federal Circuit
  • Hans Sauer, Deputy General Counsel, BIO  
  • Kevin Noonan, Ph.D., Partner, McDonnell Boehnen Hulbert & Berghoff LLP and co-founder of Patent Docs

Featured Foley Speakers:

  • Moderated by Courtenay C. Brinckerhoff, Partner, Foley & Lardner LLP and editor of PharmaPatents Blog
  • Hosted by Harold C. Wegner, Partner, Foley & Lardner LLP

For more information, please contact Meg Ryan at mryan@foley.com.

Foley & Lardner LLP will apply for CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of one General credit. Foley & Lardner LLP is a State Bar of California MCLE approved provider. Please note that participants must log in to both the teleconference and LiveMeeting portions on the date of the event; credit may not be obtained by viewing and/or listening to a program recording after the event.

Related Services

The Supreme Court Decision(s) in Myriad: What Did the Justices Say? What Does it Mean for Industry?

Location

Web Conference

Contact Information

Meg Ryan
mryan@foley.com